MARLBOROUGH, Mass.,
Dec. 1, 2017 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company
developing a new class of RNAi-based therapeutics and the Center
for Cancer Immune Therapy (CCIT) at Herlev Hospital, a leading
European center for use of tumor infiltrating lymphocytes (TIL) for
adoptive T-cell therapy (ACT), today announced that they have
entered into a collaborative research agreement to evaluate the
potential of RXi's novel self-delivering RNAi (sd-rxRNA®)
technology platform in TILs for the use in treatment for a number
of cancer types, including melanoma and ovarian cancer.
Logo:
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Dr. Karen Bulock, Vice President
of Research at RXi Pharmaceuticals said, "Immunotherapy treatments
have shown significant promise in extending the lifespan of
previously untreatable cancer patients. We are excited to
work with the extraordinary scientific leaders at the CCIT to
evaluate the advantages of our therapeutic sd-rxRNA compounds in
various cancer models." She further added that, "This
research collaboration, in combination with other collaborations we
have announced, are going to be key cornerstones in our efforts to
translate positive results into a clinical setting which we hope to
achieve within the next 12-18 months."
Professor and Director at CCIT, Inge
Marie Svane, MD, Ph.D., said that, "Over the course of the
last few years, the CCIT has carried out numerous clinical trials
based on a direct translation of the discoveries from the
laboratory. We are excited to test the potential of RXi's
innovative self-delivering RNAi technology platform to potentiate
TILs for ACT."
About Center for Cancer Immune Therapy at Herlev
Hospital
Established in October 2006, the
CCIT is a fusion between the Tumor Immunology Group, Danish Cancer
Society and the Immunotherapy Group, Copenhagen University Hospital, Herlev. CCIT aims
to bridge the gap between discovery and clinical implementation in
the field of cancer immunotherapy. CCIT has a focus on the
development of immunological treatment of cancer and has a research
profile based on equally weighted experimental and clinical
projects facilitating quick clinical implementation of new
immunotherapies. It is the leading European center for the use of
tumor infiltrating lymphocytes (TIL) for adoptive T-cell therapy
(ACT) for metastatic melanoma. CCIT provides the infrastructure of
certified clinical grade laboratory for preparation of therapeutic
cellular products and evaluations of immune responses. For
additional information, visit the CCIT website
www.herlevhospital.dk/ccit-denmark
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including self-delivering RNA
(sd-rxRNA®) compounds, that have the ability to highly selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-and-the-center-for-cancer-immune-therapy-at-herlev-hospital-announce-research-collaboration-300565009.html
SOURCE RXi Pharmaceuticals Corporation